Anaptysbio (ANAB) Common Equity (2016 - 2026)
Anaptysbio's (ANAB) quarterly Common Equity came in at $12.7 million in Q1 2026, down 62.53% YoY from $34.0 million in Q1 2025, and down 65.74% on a QoQ basis from $37.2 million in Q4 2025.
Anaptysbio (ANAB) Common Equity (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Common Equity data on file, last reported at $12.7 million in Q1 2026.
- Quarterly Common Equity fell 62.53% year-over-year to $12.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.7 million (down 62.53% YoY) and the FY2025 annual result came in at $37.2 million, down 47.49% from the prior year.
- Common Equity fell to $12.7 million in Q1 2026, from $37.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $330.7 million in Q1 2022 to a low of -$44.7 million in Q2 2025.
- A 5-year average of $114.4 million and a median of $84.4 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity dropped 13.4% — and 2025, when it sank 552.81%.
- Tracing ANAB's Common Equity over 5 years: stood at $262.1 million in 2022, then slumped by 66.39% to $88.1 million in 2023, then declined by 19.56% to $70.9 million in 2024, then tumbled by 47.49% to $37.2 million in 2025, then tumbled by 65.74% to $12.7 million in 2026.
- The last three Common Equity figures came in at $12.7 million (Q1 2026), $37.2 million (Q4 2025), and -$29.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | 12.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.75 Mn |
| Dec 31, 2025 | 37.21 Mn |
| Sep 30, 2025 | -29.42 Mn |
| Jun 30, 2025 | -44.73 Mn |
| Mar 31, 2025 | 34.02 Mn |
| Dec 31, 2024 | 70.87 Mn |
| Sep 30, 2024 | 84.37 Mn |
| Jun 30, 2024 | 9.88 Mn |
| Mar 31, 2024 | 47.78 Mn |
| Dec 31, 2023 | 88.10 Mn |
| Sep 30, 2023 | 120.38 Mn |
| Jun 30, 2023 | 148.45 Mn |
| Mar 31, 2023 | 191.09 Mn |
| Dec 31, 2022 | 262.10 Mn |
| Sep 30, 2022 | 277.62 Mn |
| Jun 30, 2022 | 304.31 Mn |
| Mar 31, 2022 | 330.75 Mn |
| Dec 31, 2021 | 356.43 Mn |
| Sep 30, 2021 | 383.61 Mn |
| Jun 30, 2021 | 385.73 Mn |